NMPA Releases 84th Batch of Reference Drugs for GQCE and First Batch Stripped of Status
The National Medical Products Administration (NMPA) has released the 84th batch of reference drugs for...
Policy / Regulatory
China’s CDE Releases 88th Batch of Reference Preparations for Generic Drug Evaluation
The Center for Drug Evaluation (CDE) in China has announced its 88th batch of reference...
National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate
The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than...
NMPA’s CDE Prioritizes Marketing Filings for Innovative Drugs with Priority Review Status
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) released a...
China’s Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...
Jiangxi Province to Implement Direct Medical Insurance Fund Payments for NRDL Drugs from December 2024
The Jiangxi Province Healthcare Security Administration and the Jiangxi Provincial Department of Finance have jointly...
China’s NHSA Sets October Dates for National Reimbursement Drug List Negotiations and Price Bidding
The National Healthcare Security Administration (NHSA) has announced that the one-site negotiation and price bidding...
China’s NMPA and Denmark’s Medicines Agency Commit to Enhanced Regulatory Cooperation
The National Medical Products Administration (NMPA) of China and the Danish Medicines Agency have signed...
NMPA’s Center for Drug Evaluation Issues New Guidelines for Domestic Transfer of Overseas-Produced Vaccines
The Center for Drug Evaluation under the National Medical Products Administration (NMPA) has issued the...
China’s NMPA Launches Pilot Program for Phased Manufacturing of Biological Products
The National Medical Products Administration (NMPA) has officially released the “Pilot Work Plan for Phased...
Hunan Province Launches Pilot Program for Retail Sales of VBP Drugs with Strict Guidelines
The Hunan Healthcare Security Administration has released the “Pilot Implementation Plan for Volume-based Procurement (VBP)...
Guangzhou Releases First Batch of Innovative Drugs and Medical Devices List, Featuring Local Companies
The Guangzhou Municipal Industry and Information Technology Bureau has unveiled the first batch of innovative...
China’s NMPA Greenlights Pilot Plan for Phased Manufacturing of Biological Products
The National Medical Products Administration (NMPA) has given its stamp of approval to the “Pilot...
Tianjin Municipality Unveils Plan to Boost Synthetic Biology and Biomanufacturing Innovation
The People’s Government of Tianjin Municipality has unveiled two significant implementation plans to bolster the...
China’s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List
According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding...
Chengdu Drafts Comprehensive Policy to Stimulate Biomedical Industry Growth
The Chengdu Municipal Bureau of Economic and Information Technology has unveiled a draft proposal titled...
NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud
The National Healthcare Security Administration (NHSA) has issued a notification aimed at standardizing the management...
Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024
On October 16, 2024, Shanxi Province’s drug procurement platform announced a notice regarding the submission...
Beijing Aims to Build a Leading Cell and Gene Therapy Hub by 2026 with New Action Plan
The Beijing Municipal Science & Technology Commission, in conjunction with the Administrative Commission of Zhongguancun...
NMPA Sets Forthcoming Guidelines for Domestic Drug Refiling Procedures
The National Medical Products Administration (NMPA) has issued a notification outlining the requirements for the...